Review of outcome measurement instruments in Alzheimer's disease drug trials: Introduction

被引:12
作者
Demers, L
Oremus, M
Perrault, A
Wolfson, C
机构
[1] Jewish Gen Hosp, Ctr Clin Epidemiol & Community Studies, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Biostat & Epidemiol, Montreal, PQ H3A 2T5, Canada
[3] McGill Univ, Dept Occupat Hlth, Montreal, PQ H3A 2T5, Canada
[4] Inst Univ Geriatr Montreal, Ctr Rech, Montreal, PQ, Canada
关键词
D O I
10.1177/089198870001300401
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
This article introduces a four-part series on outcome scales used in Alzheimer's disease drug trials. First, it discusses the division of scales into four domains: cognition, functional ability/quality of life, behavior/mood, and global. Within each domain, the shortcomings of existing literature reviews are outlined, and the need for a more coherent view of the psychometric properties of the scales is emphasized. Second, the key concepts of reliability, validity, and responsiveness to change are defined and explained. This explanation also provides an overview of the statistical techniques used to assess measurement properties. Finally, the methods used to select the scales for review in the subsequent articles are explained, and each article is briefly introduced.
引用
收藏
页码:161 / 169
页数:9
相关论文
共 83 条
  • [1] CONSENSUS CONFERENCE ON THE METHODOLOGY OF CLINICAL-TRIALS OF NOOTROPICS, MUNICH, JUNE 1989 - REPORT OF THE CONSENSUS COMMITTEE
    AMADUCCI, L
    ANGST, J
    BECH, P
    BENKERT, O
    BRUINVELS, J
    ENGEL, RR
    GOTTFRIES, CG
    HIPPIUS, H
    LEVY, R
    LINGJAERDE, O
    LOPEZIBOR, JJ
    ORGOGOZO, JM
    PULL, C
    SALETU, B
    STOLL, KD
    WOGGON, B
    [J]. PHARMACOPSYCHIATRY, 1990, 23 (04) : 171 - 175
  • [2] [Anonymous], DRUG TREATMENTS ALZH
  • [3] [Anonymous], NEUROPSYCHOLOGY ALZH
  • [4] [Anonymous], HLTH EC DEMENTIA
  • [5] Antuono P, 1997, ALZ DIS ASSOC DIS, V11, P22
  • [6] Effects of metrifonate on cognitive decline in Alzheimer disease: A double-blind, placebo-controlled, 6-month study
    Becker, RE
    Colliver, JA
    Markwell, SJ
    Moriearty, PL
    Unni, LK
    Vicari, S
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1998, 12 (01) : 54 - 57
  • [7] Double-blind placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease
    Becker, RE
    Colliver, JA
    Markwell, SJ
    Moriearty, PL
    Unni, LK
    Vicari, S
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1996, 10 (03) : 124 - 131
  • [8] EFFECTS OF IDEBENONE IN ELDERLY SUBJECTS WITH COGNITIVE DECLINE - RESULTS OF A MULTICENTER CLINICAL-TRIAL
    BERGAMASCO, B
    VILLARDITA, C
    COPPI, R
    [J]. ARCHIVES OF GERONTOLOGY AND GERIATRICS, 1992, 15 (03) : 279 - 286
  • [9] Factors determining interrater agreement with rating global change in dementia: The CIBIC-plus
    Boothby, H
    Mann, AH
    Barker, A
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 1995, 10 (12) : 1037 - 1045
  • [10] Bowling A, 1995, Measuring disease: A review of disease-specific quality of life measurement scales